At Erciyes University, the first dose of the local corona vaccine ERUCOV-VAC was administered to 44 volunteers. Now the countdown has begun for the second dose of Phase 1 phase. Rector Çalış announced that the third phase will be started in February.
At Erciyes University (ERU) in Kayseri, an important stage has been reached in domestic COVID-19 vaccine studies. The first dose of the ERUCOV-VAC inactive vaccine candidate, which was developed by the Vaccine Research and Development Application and Research Center (ERAGEM) and produced under GMP conditions at Koçak Farma, was administered to 44 volunteers at Erciyes University after the approval of the ethics committee and approval from the Ministry of Health. The countdown has now begun for the second dose of Phase 1. It was reported that the second dose will be administered to the same volunteers as of today.
NO SIDE EFFECTS
Providing information about the studies, ERÜ Rector Prof. Dr. Mustafa Çalış said, “Fortunately, no side effects were observed in our 44 volunteers. We will now give the second dosing to the same volunteers. We hope that after the second dosing is finished on December 15th, there will be good results here, and we plan to switch to Phase 2 study as soon as possible. It is very difficult to give an exact date. But as of February, we hope to complete the Phase 2 study and switch to Phase 3, “he said.